bortezomib + lenalidomide + dexamethasone + fenofibrate

This regimen is a **combination of four drugs**: **bortezomib**, **lenalidomide**, **dexamethasone**, and **fenofibrate**. Bortezomib is a proteasome inhibitor that disrupts protein degradation, leading to apoptosis of cancer cells. Lenalidomide is an immunomodulatory agent that inhibits tumor growth and angiogenesis and enhances immune cell activity. Dexamethasone is a synthetic glucocorticoid corticosteroid that suppresses inflammation and immune responses. Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist primarily used as a lipid-lowering agent; it modulates lipid metabolism and may have off-label anticancer or anti-inflammatory effects, though clinical evidence for its role in multiple myeloma is limited. This specific combination is not a standard or FDA-approved regimen for any disease; however, the three-drug combination of bortezomib, lenalidomide, and dexamethasone is widely approved and used as standard induction therapy for newly diagnosed multiple myeloma, both for transplant-eligible and ineligible patients, with established efficacy and safety[1][3][5][7][8]. Fenofibrate is not part of any recognized myeloma combination in authoritative guidelines or clinical evidence. Its addition to this regimen would be experimental and not standard of care.